Aptamer‐modified tetrahedral DNA nanostructure‐immobilized liposome for specific gene delivery and potential cancer theragnostic

Abstract Targeted delivery of therapeutic agents to cancer cells is crucial for effective cancer treatment without adverse effects. In this study, we developed a novel delivery carrier, Aptamer‐modified tetrahedral DNA nanostructure (TDN) immobilized Liposome (ApTL), for specific delivery to nucleolin‐overexpressing cancer cells. We demonstrated that targeted ApTL was highly effective in delivering plasmid and mRNA to nucleolin‐overexpressing cancer cells compared to non‐targeted ApTL with a non‐specific aptamer. ApTL, which is highly negative and nano‐sized, specifically delivered nucleic acids to MDA‐MB‐231 and HeLa cancer cells, primarily via lipid‐raft‐mediated endocytosis. Furthermore, the co‐delivery of mRNA and doxorubicin resulted in increased apoptosis and reduced cancer cell viability. Interestingly, co‐delivery of mRNA and Dox did not show a significant difference in EGFP expression at 24 h but dramatically increased EGFP expression at 48 h, making ApTL/mEGFP/Dox a promising candidate for detecting live cancer cells after targeted cancer drug treatment. Our results suggest that ApTL can be a promising tool for the targeted delivery of therapeutic agents to nucleolin‐overexpressing cancer cells, providing a new strategy for cancer theragnostic.